Cellvizio by Mauna Kea Technologies

Directions Website

Cellvizio by Mauna Kea Technologies Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine.

10/15/2026

Prof. Dr. med. Jost Langhorst explains the clinical turning point that led him to integrate , powered by , into his department.

Facing patient after patient with long histories of persistent digestive distress, surface-level management was no longer enough.

See how this approach can better support your chronic patients: https://hubs.la/Q04BgXtN0

10/13/2026

often begins as small nodules making early and accurate diagnosis crucial for improving treatment outcomes and increasing survival rates. Learn how Professor Stéphane Renaud and his team at the CHRU de Nancy are leveraging to transform patient care: https://hubs.ly/Q04B0KFw0

An early & accurate diagnosis of lung nodules allows timely surgical resection of malignancy while avoiding unnecessary ...
10/09/2026

An early & accurate diagnosis of lung nodules allows timely surgical resection of malignancy while avoiding unnecessary surgery. For , take a moment to learn how Cellvizio can capture images from inside a lung lesion in real time, in vivo, providing the advantage of unique visibility and information: https://hubs.la/Q04zND_s0

10/06/2026

Prof. Jost Langhorst, MD captures a visible, real-time change on the intestinal surface during the powered by test.

Watch in full: https://hubs.la/Q04ymLv30

09/29/2026

The stakes for have never been higher. For physicians, the challenge isn't just finding visible lesions, it’s spotting flat, hidden dysplasia before it progresses.

"Any patient with Barrett's is a good candidate for Cellvizio." -Kamran Ayub, MD, MRCP, FASGE

https://hubs.la/Q04yff_m0

We’re heading to DC for the 2026 American Foregut Society Annual Meeting! As a proud exhibitor, we’re looking forward to...
09/24/2026

We’re heading to DC for the 2026 American Foregut Society Annual Meeting! As a proud exhibitor, we’re looking forward to connecting with specialists, sharing the latest clinical data, and joining the conversations driving what’s next in foregut care. Stop by and say hello at Booth 7.

09/22/2026

For millions suffering from persistent food-related symptoms, powered by offers a new path to elevate daily quality of life.

What does this breakthrough actually mean for patient care? Dr. Maryan Cavicchi (Clinique Paris Bercy) weighs in during our latest interview: https://hubs.la/Q04y2lbp0

09/18/2026

is officially recommended in the European Society of Gastrointestinal Endoscopy (ESGE) guidelines for the characterization of pancreatic cystic lesions. This is a major step towards improving diagnostic accuracy and reducing unnecessary surgeries for patients worldwide.

🔬 Why adding Cellvizio matters:
✅ Improves diagnostic accuracy to 97-98%
✅ Reduces unnecessary surgeries by 23%
✅ >50% of pancreatic cysts remain inconclusive after fine-needle aspiration (EUS-FNA)

Read more: https://hubs.la/Q04xM_ld0

09/15/2026

offers unprecedented cellular-level visualization, empowering physicians to understand and treat patients with greater precision unlike any other platform available today. This groundbreaking technology is transforming the landscape of healthcare.

Discover Cellvizio's transformative impact: https://hubs.la/Q04xvt4Z0

09/10/2026

A landmark systematic review and meta-analysis published in Endoscopy International Open, conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency (NECA), delivers massive clinical validation for in upper GI cancer! Data across 33 studies and 2,350 patients indicates that real-time cellular imaging substantially improves diagnostic yield while minimizing invasive sampling.

Real the full PR: https://hubs.la/Q04x50tn0

Address

24 Denby Road, Suite 140
Boston, MA
02134

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Cellvizio by Mauna Kea Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share